Caplyta Starting Dosage for Major Depressive Disorder
The recommended starting dose of Caplyta (lumateperone) for major depressive disorder is 42 mg once daily, taken orally with or without food, with no dose titration required. 1
Dosing Specifications
Standard Starting Dose:
- 42 mg once daily is the FDA-approved starting and maintenance dose for MDD 1
- No titration needed - start at full therapeutic dose 1
- Can be taken with or without food 1
- Administered in the evening 2
Dose Adjustments Required in Specific Situations
Hepatic Impairment:
- Moderate or severe hepatic impairment (Child-Pugh class B or C): Reduce to 21 mg once daily 1
Drug Interactions with CYP3A4 Inhibitors:
- Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): Reduce to 10.5 mg once daily 1
- Moderate CYP3A4 inhibitors (e.g., diltiazem, fluconazole): Reduce to 21 mg once daily 1
CYP3A4 Inducers:
- Avoid concomitant use entirely 1
Clinical Context
Caplyta is FDA-approved as adjunctive therapy to antidepressants in adults with MDD who have inadequate response to 1-2 antidepressant trials in the current episode 2, 3. The evidence base comes from two Phase 3 trials demonstrating significant improvement in depressive symptoms when added to ongoing antidepressant therapy, with effect sizes of -0.56 to -0.61 on the MADRS total score 2, 3.
Important Safety Considerations
Black Box Warnings:
- Increased mortality risk in elderly patients with dementia-related psychosis (not approved for this use) 1
- Increased risk of suicidal thoughts/behaviors in pediatric and young adult patients - close monitoring required within 1-2 weeks of initiation 1
Common Adverse Effects (≥5% and twice placebo rate):
Key Safety Advantages:
- Minimal weight gain risk (0.4% with ≥7% weight increase) 4
- Low extrapyramidal symptom risk 4, 2
- Minimal cardiometabolic effects 4, 2
Monitoring Requirements
- Assess therapeutic response and adverse effects regularly beginning within 1-2 weeks of initiation 1
- Monitor for emergence of suicidal ideation, agitation, or behavioral changes, particularly in the first 1-2 months 1
- Consider treatment modification if inadequate response after 6-8 weeks (general antidepressant guidance) 5
Clinical Pitfalls to Avoid
- Do not titrate - the 42 mg dose is both the starting and therapeutic dose 1
- Do not forget dose adjustments for hepatic impairment or CYP3A4 inhibitor co-administration 1
- Do not use in pediatric patients - safety and efficacy not established 1
- Monitor discontinuation rates - 8.7-12.4% discontinued due to adverse events in clinical trials, primarily due to tolerability issues 4, 2, 3